Company intelligence / Profile preview

Novlead Biotech

Ownership: Private
Development stage: Other

Overview

Novlead Biotech has commercialized two Class III and eight Class II medical devices in China, with additional products under development. Their eNOaire series enables instant, on-demand generation and delivery of nitric oxide for therapeutic use, particularly in pulmonary hypertension. The company’s technology platform allows precise control of NO concentration and real-time monitoring to ensure safety. Clinical results support the efficacy of their devices for improving oxygenation by selective pulmonary vasodilation

Therapeutic areas: Infectious DiseasesPulmonologyCardiovascularNeurology
Modalities: DeviceGas therapy (Nitric oxide delivery)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Novlead Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novlead Biotech.

Explore the full profile